Time for investors to be fearful, not greedy – and sell?
The Covid-19 crash proved a great investment opportunity. Does the vaccine mean it’s time to sell?


“Buy on the sound of cannons, sell on the sound of trumpets.” So runs the old investment adage, apocryphally attributed to a member of the Rothschild banking dynasty. The idea – that you should invest when everyone is panicking and assets are cheap, and sell when everyone is jubilant, and assets are expensive – makes perfect contrarian sense. Investing in March this year, when fear of coronavirus and its impact was at a peak, certainly took a lot of nerve, but the level of panic was unmistakable. Today the question is: as vaccine news sends many markets to new highs, is this the “trumpet” moment?
Not yet, perhaps – but we might be getting close. One sentiment survey that I like to watch – the monthly survey of global fund managers from Michael Hartnett’s team at Bank of America (BoA) – is flashing a few warning signs that big investors might be getting ahead of themselves. The fact that this month’s was the most bullish survey of the year so far isn’t a surprise given the year we’ve had. But significantly, the levels of cash held by fund managers have fallen sharply from 4.4% to 4.1%. That’s below the 4.2% recorded in January, before Covid-19 had gripped the public consciousness anywhere outside of China. More importantly, based on past readings, below 4% is a “sell” signal, notes BoA.
There are still areas that will benefit from the “reopening” trade – there has been a big shift (or “rotation”, as City traders like to describe it) into the sectors which suffered most during the Covid-19 sell-off – emerging markets and small companies have seen particularly large flows of money in the past month, along with banks and value stocks generally. What investments still look neglected? At a market level, the eurozone and Japan are still lagging, while the UK remains widely disliked (a constant in this survey since the 2016 vote for Brexit). But even Britain is less hated than the energy sector.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
In short, if you’re looking for good bets today, stick with value stocks and beneficiaries of re-opening, and be long Japan, the eurozone, the UK and energy. But be ready for a bumpier ride in 2021 when good economic news could spell pain for wider markets.
That brings us to one other point from the survey that’s worth pulling out: despite their belief in a relatively strong recovery, global fund managers are still remarkably complacent about inflation. While most expect prices to rise next year, only 4% anticipate that inflation will be “a lot higher”. Instead, a majority are still backing the conveniently ideal scenario of “above-trend growth and below-trend inflation”. A surprise resurgence of inflation next year is exactly the sort of scenario that could derail markets. So hang on to your gold (and bitcoin).
I wish I knew what carried interest was, but I’m too embarrassed to ask
“Carried interest” or “carry” is a perk enjoyed mainly by private equity executives. In short, it’s a performance fee. The managers typically take a 20% share of the profits of a fund (on top of management fees) with the idea that this aligns their interests more closely with the investors.
Note that the name “carried interest” has nothing to do with the interest you might get paid on your savings. The term originates with trade voyages in the 16th century, where captains of ships sailing from Europe to Asia or America would take a 20% share of the profit.
You might question why a performance fee would make an investment manager try harder to make good investments, but that’s not the most controversial thing about carried interest. The real issue is that it is taxed as a capital gain rather than income, and so incurs a lower tax rate. In the UK for example, the capital gains tax top rate is 28% – it’s 45% for income tax (see page 10).
One argument for taxing capital gains less aggressively than income is to encourage entrepreneurship and investment – the idea being that those who put their own capital at risk to set up or invest in a business should get to retain more of any gains they make by doing so. This makes carried interest contentious, because while there are a few defenders of “carry”, most argue that private equity executives are in effect getting a preferential tax rate on what in any other industry would simply be viewed as a bonus for doing your job, and therefore taxed as income.
Changing the rules on carried interest would not raise much tax. A study by the University of Warwick and the London School of Economics found that taxing “carry” as income in the UK would have raised just £440m in 2017. It might also have unintended consequences in terms of driving the industry elsewhere. However, the argument for fairer tax treatment is politically potent at a time when inequality is never far from the headlines.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
John Stepek is a senior reporter at Bloomberg News and a former editor of MoneyWeek magazine. He graduated from Strathclyde University with a degree in psychology in 1996 and has always been fascinated by the gap between the way the market works in theory and the way it works in practice, and by how our deep-rooted instincts work against our best interests as investors.
He started out in journalism by writing articles about the specific business challenges facing family firms. In 2003, he took a job on the finance desk of Teletext, where he spent two years covering the markets and breaking financial news.
His work has been published in Families in Business, Shares magazine, Spear's Magazine, The Sunday Times, and The Spectator among others. He has also appeared as an expert commentator on BBC Radio 4's Today programme, BBC Radio Scotland, Newsnight, Daily Politics and Bloomberg. His first book, on contrarian investing, The Sceptical Investor, was released in March 2019. You can follow John on Twitter at @john_stepek.
-
Trump wants to colonise Mars – will it happen?
Donald Trump wants to plant the US flag on Mars. Could humans really live there?
By Simon Wilson
-
Klarna postpones US IPO as Trump's tariffs rattle markets
Buy-now-pay-later lender Klarna has postponed its US initial public offering owing to the market turbulence. It is not alone, says Matthew Partridge
By Dr Matthew Partridge
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves
-
India's stock market decline wipes out $1.3 trillion in market value – can investors stay optimistic?
More than $1 trillion has been wiped off from India's stock market after investors turn to China. Has the emerging-market darling hit rock bottom?
By Alex Rankine
-
Pensions revolution: how to profit from the trends shaping the UK pension system
The UK pension system is one of the biggest in the world. Big changes are under way, says Rupert Hargreaves
By Rupert Hargreaves